11th Dec 2020 21:47
PureTech Health PLC - Boston, Massachusetts-based biotherapeutics company - On Thursday, says it has started a phase 2a proof-of-concept study of LYT-100 in patients with breast cancer-related, upper limb secondary lymphedema, a chronic and progressive disorder for which there are no US Food & Drug Administration-approved drug therapies.
LYT-100 is PureTech's wholly-owned product candidate that is being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow.
Current stock price: 315.00 pence
Year-to-date change: down 1.6%
By Lucy Heming;Â [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech